Physician profile
Yaneth Trujillo
NPI 1184753246
$3,188.33
in general payments reported to CMS, 2019-2025
33 companies · $487 in 2025
The $487 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $452 · 2021: $285 · 2022: $75.21 · 2023: $466 · 2024: $937 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,890.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $739.15 | 2020-2025 | Airsupra, Andexxa, Farxiga |
| Lilly USA, LLC | $332.38 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.22 | 2019-2021 | |
| Pfizer INC. | $243.21 | 2019-2025 | |
| Novo Nordisk INC | $207.44 | 2019-2025 | Wegovy |
| Amarin Pharma, INC. | $200.64 | 2019-2021 | |
| Amgen INC. | $175.37 | 2023-2025 | Otezla, Repatha, Repatha |
| Ani Pharmaceuticals, INC. | $159.96 | 2024-2025 | Purified Cortrophin Gel |
| Abbott Laboratories | $133.27 | 2023-2025 | Proclaim, Freestyle Libre 3 |
| Boston Scientific Corporation | $123.44 | 2021 | |
| Dexcom, INC. | $118.73 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $115.12 | 2023-2025 | Cologuard Collection Kit |
| Redhill Biopharma INC. | $42.60 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.49 | 2023-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $34.94 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $32.88 | 2019-2020 | |
| Glaxosmithkline, LLC. | $31.44 | 2020-2023 | Arexvy |
| Gilead Sciences, INC. | $30.50 | 2020 | |
| Tactile Systems Technology INC | $25.36 | 2025 | Flexitouch Plus, Nimbl |
| Eisai INC. | $20.98 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.23 | 2020 | |
| Allergan, INC. | $18.36 | 2020 | |
| Sanofi Pasteur INC. | $16.96 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $16.27 | 2019 | |
| Phadia US INC. | $15.84 | 2023 | Immunocap |
| Abbvie INC. | $15.45 | 2023 | Ubrelvy, Synthroid |
| Novartis Pharmaceuticals Corporation | $15.31 | 2020 | |
| Vivus LLC | $14.79 | 2020 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yaneth Trujillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.